C3G

Jan 26, 2026

Summary  Sobi has received European Commission approval for ASPAVELI (pegcetacoplan) to treat C3G and primary IC-MPGN, two rare, progressive kidney diseases. The approval follows a positive CHMP opinion (December 2025) and marks the first approved treatment for primary IC-MPGN and the first for both C3G...

Jan 20, 2026

Nxera Pharma Reports Positive Phase 3 Trial Results for Daridorexant in South Korea Nxera Pharma announced top-line results from its pivotal Phase 3 clinical trial of daridorexant in South Korea, showing that the study successfully met both primary and secondary endpoints in adult and elderly patients with insom...

Feb 19, 2024

Complement 3 glomerulopathy (C3G) is a form of glomerular disease where there’s a notable presence of C3 complement component deposits in the glomeruli. These deposits occur without significant amounts of immunoglobulin and without the deposition of C1q and C4. The buildup of C3, without much classical or lectin co...

Nov 09, 2020

Rare renal disorders are the fifth most prominent reason behind the cause of end-stage kidney disease (ESKD), ultimately leading to kidney failure, and damage to other tissues.  Among such rare kidney diseases, one is complement 3 glomerulopathy (C3G). Albeit rare, the total diagnosed C3G prevalent population ...